Dec 9, 2023 · In a large single-arm phase 2 trial, the anti-PD-1 inhibitor tislelizumab combined with the next-generation BTK inhibitor zanubrutinib had an overall response rate of 58.3% and …

The most common adverse events were infections (18.0%), gastrointestinal disorders (13.0%) and hematological toxicities (11.4%). These data suggest that combined checkpoint and BTK …

Nov 2, 2023 · Combined checkpoint and BTK inhibition by tislelizumab plus zanubrutinib is an effective and well-tolerated treatment strategy for pts with RT. Responses are durable and …

Response‐adapted zanubrutinib and tislelizumab potentially enhances the efficacy of CAR T‐cell therapy with a favourable safety profile in R/R LBCL, effectively counteracting T‐cell …

Aug 8, 2024 · A combination of tislelizumab plus zanubrutinib is effective and well-tolerated for patients with Richter’s transformation. Having 3 out of 4 patients still alive after one year is …

Dec 20, 2023 · The phase II, international, prospective, open-label study was led by Othman Al-Sawaf, MD, of the Center for Integrated Oncology Aachen Bonn Köln Düsseldorf in …

Nov 2, 2023 · Conclusions Combined checkpoint and BTK inhibition by tislelizumab plus zanubrutinib is an effective and well-tolerated treatment strat- egy for pts with RT. Responses …

Apr 23, 2025 · Patients received zanubrutinib or tislelizumab with appropriate dose modifications and interruptions. For grade 4 haematological adverse events (AEs), or grade ≥ 3 non …

Jan 18, 2024 · Major Finding: Patients with Richter transformation (RT) receiving tislelizumab plus zanubrutinib showed manageable toxicity and had an ORR of 58.3%. Concept: The …

BGB-3111-A317-001 (NCT02795182) was a 2-part, phase 1/2, open-label study (13 sites in Australia and China) evaluating the safety and preliminary efficacy of zanubrutinib in …